spacer
home > ebr > > robotics in pharmaceutical research
PUBLICATIONS
European Biopharmaceutical Review

Robotics in Pharmaceutical Research

'Robot' is a Czech word meaning worker, from the play RUR: Rossums' Universal Robots by the Bohemian writer Karel Capek. The robot has since become an inspiration for science fiction writers and for engineers. Of course the science fiction vision of a robot is a mechanical man, but the reality we see in industry is simply a robotic arm. This is a versatile programmable manipulator, an integration of mechanics, electronics and software, designed interdependently to produce the mechanical equivalent of the computer - an undedicated machine unable to do anything until we program it.

In the pharmaceutical lab it is even less than that definition; the term 'robot' being applied to programmable liquid handlers. Drug development requires the screening of hundreds or thousands of samples and it is in this field that the robot arm is a vital tool. Such an automated screening system is called a 'high-throughput screening' (HTS) system.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By David N Sands, CEO and Founder of ST Robotics International

David N Sands was educated in London. He founded Sands-Whiteley Research and Development, which concentrated on advanced electronics and industrial automation using mini-computers and later microprocessors. David was a Department of Industry Consultant on microprocessors for many years. In 1982 the first robots were designed and Cyber Robotics, which was later sold to the Bibby Corporation, was formed the same year.

David wrote the first robot software, ROBOFORTH, in 1982 and designed the first robot controller in 1985. In 1989 he formed Sands Technology with Catherine George and ST-Monforte Robotics with Mathew Monforte in Trenton, New Jersey, in 1991. Sands Technology International Inc was formed in 1992 with Mathew Monforte as Vice President.
 

spacer
David N Sands
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Source BioScience invest in digital pathology platform to enhance the outsourced histopathology service solution provided to the NHS and private healthcare

As a leading provider of outsourced histopathology services to the NHS and private healthcare centres in the UK Source BioScience has, after a detailed review of all other available alternatives in the digital marketplace, unveiled investment in a digital pathology platform from their preferred partner, Philips.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 
Industry Events

Symposium on Digitalization and Big Data in Biotech and Pharma

6 June 2018, ETH Zurich, Institute for Chemical and Bioengineering, Vladimir-Prelog-Weg 1

The Symposium on Digitalization and Big Data in Biotech & Pharma will bring together experts and key stakeholders from industry and academia to discuss and current digital innovations and technological trends in the pharmaceutical sector.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement